Improvement of zoledronic acid-induced jaw osteonecrosis with bortezomib

Acta Haematologica

Volumn 118, Issue 4, 2008, Pages 203-204

  Timuraǧaoǧlu, Ayşen ^a   Özkaynak, Can ^a   Tüzüner, Serdar ^a   Bostan, Feyzi ^a   Ündar, Levent ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; SULTAMICILLIN; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE BIOPSY; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; FEMALE; GINGIVA HYPERPLASIA; HUMAN; INFLAMMATION; JAW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; OSTEOMYELITIS; PRIORITY JOURNAL; TOOTH EXTRACTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DIPHOSPHONATES; DOXORUBICIN; FEMALE; HUMANS; IMIDAZOLES; MANDIBULAR DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEASE INHIBITORS; PYRAZINES; TOOTH EXTRACTION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 38749097751     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110804     Document Type: Article

References (8)

1. Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003;81:235-245.
2. Rajkumar VS, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639.
3. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini PG: Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-1128.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
5. Richardson PG: A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 2004;5:1321-1331.
6. Heider U, Kaiser M, Müller C, Jakob C, Zavrsk I, Schulz C-O, Fleissner C, Hecht M, Sezer O: Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-238.
7. Peles S, Fisher NM, Gao F, Steven MD, Tomasson MH, DiPersio JF, Vij R: Once weekly bortezomib (Velcade) preserves bone health by a direct effect on osteoclast function independent of its effect on the malignant plasma cells. Blood (ASH Annual Meeting Abstracts) 2005;106:abstract 3458.
8. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang S-H, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G: Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131;71-73.